Introduction
============

Tuberculosis (TB) is a global health problem. According to the World Health Organization (WHO) report, there were an estimated 10.4 million new TB cases worldwide in 2015, of which 480,000 cases were multidrug-resistant TB (MDR-TB), and an additional 100,000 cases were rifampin (RIF)-resistant TB that were also newly eligible for MDR-TB treatment[@B1]. In Korea, isoniazid (INH) resistance rates were 9.9% in new patients and 24.1% in retreatment patients[@B2]. The rate of MDR-TB among new TB cases increased from 2.7% in 2004 to 2.9% in 2008[@B2], and there were 30,892 new TB cases in 2016, of which 852 cases were MDR-TB[@B3].

It is important to quickly identify the results of drug susceptibility testing (DST) in patients at increased risk of drug resistance and to choose individualized treatment regimens based on DST profiles. Korean guidelines for TB, issued in 2017, recommend that genotypic RIF resistance should be treated as MDR-TB until conventional DST results are identified[@B4]. Early detection of drug resistance allows immediate and effective treatment, which improves the prognosis and prevents MDR strains from transmission as well as acquisition of additional resistance. Although conventional DST using liquid media culture has shortened the time to 2 weeks compared to solid media culture using Löwenstein-Jensen (LJ) medium, recent advances in molecular tools, such as the detection of mutations associated with drug resistance, have helped to detect drug resistance earlier. Based on this, the WHO recommended the use of molecular line probe assays (LPAs) for rapid detection of MDR-TB in 2016[@B5].

The GenoType MTBDR*plus* assay (MTBDR*plus* assay; Hain Lifescience, Nehren, Germany) is a rapid molecular diagnostic test that simultaneously detects the presence or absence of *Mycobacterium tuberculosis* and mutations causing resistance to specific drugs[@B6]. This assay is one of the commercial versions of LPAs that detect drug resistance to RIF and INH relying on specific probes immobilized on nitrocellulose strips. INH resistance is known to be mostly related with mutations in *katG* and *inhA* gene[@B7][@B8][@B9]. Mutations in *katG* have been found to be associated with a high-level INH resistance, while *inhA* mutations produce both low-level resistance to INH and high-level resistance to prothionamide (Pto), which is used for the treatment of MDR-TB[@B10][@B11][@B12][@B13][@B14]. Cross-resistance to Pto may occur in patients who had received INH but had never been treated with Pto[@B15], and the frequency of cross-resistance in Korea has been reported to be 50%[@B16].

Currently, Pto resistance can only be detected by phenotypic susceptibility test; however, the result of this test is often questioned due to low reliability and reproducibility[@B17]. Therefore, verifying the presence of *inhA* mutation helps determine the use of Pto in cases of MDR-TB before conventional DST is confirmed. Nevertheless, few studies have reported the correlation between the results of the MTBDR*plus* assay and phenotypic DST for Pto resistance.

In this study, we sought to analyze the relationship between gene mutation pattern according to the MTBDR*plus* assay and phenotypic INH and Pto susceptibility by conventional DST in patients with mutations on *katG* or *inhA* genes.

Materials and Methods
=====================

1. Study population
-------------------

This study retrospectively enrolled patients whose MTBDR*plus* assay results revealed *katG* or *inhA* gene mutations from September 2009 to October 2016 at a single tertiary referral center, Asan Medical Center, Seoul, Korea. Baseline characteristics at the time of diagnosis were gathered, including age, sex, physical examination findings, body mass index (BMI), and medical history (previous anti-TB treatment, diabetes mellitus, chronic liver disease, chronic kidney disease stage ≥2, respiratory disease, transplantation, human immunodeficiency virus infection, anti-tumor necrosis factor \[TNF\]-α therapy, and hematologic malignancy). The study was approved by the Institutional Review Board of Asan Medical Center (approval number: 2017-1012). The requirement for informed consent was waived due to the retrospective nature of the study.

2. Collection of specimens and drug susceptibility test
-------------------------------------------------------

Specimens from lung (sputum, bronchial washing by bronchofibroscopy, and lung tissue by percutaneous needle aspiration) and other involved organs (cerebrospinal fluid, intestine, lymph nodes, pleural fluid, kidney, bone, and muscle) were included. All specimens were subjected to Ziehl-Neelsen staining for examination of acid-fast bacilli (AFB) on smear and culture using both solid (Ogawa medium; Korean Institute of Tuberculosis, Cheongju, Korea) and liquid (BACTEC 960 Mycobacterial Growth Indicator Tube; Becton Dickinson, Sparks, MD, USA) media. MTBDR*plus* assay was performed on AFB-positive specimens or clinical isolates in patients with increased risk of drug resistance. Cultured clinical isolates were subjected to conventional DST. Conventional DST was evaluated by the absolute concentration method with LJ media at the Korean Institute of Tuberculosis, a Supranational TB Reference Laboratory. Growth exceeding that of the control wells by \>1% was considered to indicate drug resistance. A low-level resistance to INH was defined as resistance to 0.2 µg/mL but susceptible to 1 µg/mL of INH, while a high-level resistance was defined as resistance to INH of 1 µg/mL. Isolates were tested for resistance to RIF using concentrations of 40 µg/mL. The MTBDR*plus* assay was performed according to the manufacturer\'s instructions. The assay detects the presence or absence of wild-type (WT) and mutant DNA sequences in *rpoB*, *katG*, and *inhA* , which are known to be associated with RIF and INH resistance. There are 27 reaction lines comprising six control lines and 21 WT or mutation reaction lines (MUT) as follows: eight *rpoB* WT (codon 505 to 533) and four MUT bands (MUT1, D516V; MUT2A, H526Y; MUT2B, H526D; MUT3, S531L), one *katG* WT (S315 region), and two MUT bands (MUT1, S315T\[AGC315ACC\]; MUT2, S315T\[AGC315ACA\]), two *inhA* WT (WT1, positions −15 to −16; WT2, positions −8), and four MUT bands (MUT1, C15T; MUT2, A16G; MUT3A, T8C; MUT3B, T8A). A gene mutation indicates the presence of MUT band and/or loss of WT band.

3. Statistical analysis
-----------------------

Descriptive statistics were used to describe patient characteristics. Categorical variables were reported as counts and percentages and compared using the Pearson\'s chi-square test or Fisher exact test. Continuously measured parameters were reported as means±standard deviation and were compared using student\'s t-test. Statistical significance was indicated for p-values of \<0.05. All statistical analyses were completed using SPSS version 21.0 (IBM Corp., Armonk, NY, USA).

Results
=======

1. Baseline clinical characteristics
------------------------------------

In this retrospective study, the authors reviewed 206 patients whose MTBDR*plus* assay results revealed *katG* or *inhA* gene mutations. The most common type of infection was pulmonary TB (n=185, 89.8%) followed by disseminated TB (n=12, 5.8%) and extrapulmonary TB (total n=9, 4.4%; lymphadenitis, n=5; intestine, n=2; kidney, n=1; osteomyelitis, n=1). Specimens were obtained from sputum (n=185), bronchial washing (n=3), lung tissue (n=1), and other involved organs (lymph node, n=6; pleural fluid, n=4; cerebrospinal fluid, n=2; intestine, n=2; renal abscess, n=1; spine, n=1; muscle, n=1).

Stratifying by genotypic resistance to RIF, 54.9% isolates were found to be MDR and 45.1% were found to be INH mono-resistant by MTBDR*plus* assay ([Table 1](#T1){ref-type="table"}). Patients with MDR-TB were younger (43.0±16.1 vs. 50.9±16.9 years, p=0.001) and had a more frequent history of previous TB treatment (53.1% vs. 20.4%, p\<0.001) than those with INH mono-resistance. There was no difference in sex and BMI. Comorbidities were similar in both groups except for chronic liver disease (2.7% in MDR-TB vs. 10.8% in INH mono-resistance, p=0.017).

2. Mutation patterns of *katG* and *inhA* genes by MTBDR*plus* assay
--------------------------------------------------------------------

[Table 2](#T2){ref-type="table"} shows mutation patterns of *katG* and *inhA* genes detected by the MTBDR*plus* assay. *katG* mutations were identified in 140 of 206 isolates (68.0%) and *inhA* mutations were identified in 72 of 206 isolates (35.0%). Except for six patients with both *katG* and *inhA* mutations, MDR-TB patients had more frequent mutations in *katG* than INH mono-resistant TB patients (69.9% vs. 59.1%, p=0.107), although this difference was not statistically significant. In contrast, MDR-TB patients had significantly less frequent *inhA* mutations (25.7% vs. 39.8%, p=0.031).

3. Correlation between phenotypic and genotypic susceptibility results based on mutation patterns of *katG* and *inhA* genes
----------------------------------------------------------------------------------------------------------------------------

The concordances of the MTBDR*plus* assay and the conventional DST for the detection of INH and Pto susceptibility are shown in [Table 3](#T3){ref-type="table"}. Strains with isolated *katG* mutation presented phenotypic INH resistance in 97.0% and phenotypic Pto resistance in 8.2% of cases. Among the isolates with isolated *inhA* mutation, 78.8% were identified as phenotypic INH resistant and 31.8% as phenotypic Pto resistant. Of all genotypic INH resistant patients, 2.9% had mutations in both the *katG* and *inhA* genes, all of which were resistant to INH, and 33.3% were resistant to Pto. Except for six patients with both *katG* and *inhA* mutations, the presence of *katG* mutation presented high-level INH resistance in most cases (94.8%) while over half of the patients with *inhA* mutation (51.5%) showed low-level resistance. Of the 34 phenotypic Pto resistant isolates, 21 (61.8%) had an *inhA* mutation, 11 (32.4%) had a *katG* mutation, and two (5.9%) had both mutations.

Among the 134 strains with isolated *katG* mutation, MUT1 band was observed in 119 (88.8%) isolates, and positive MUT2 band and WT loss alone were observed in eight (6.0%) and seven (5.2%), respectively. Among the 66 isolates with isolated inhA mutation, the most common type was MUT1 (n=60, 91.0%), followed by WT1 loss alone (n=4, 6.1%) and MUT3A (n=1, 1.5%), and MUT3B (n=1, 1.5%). Among 127 strains with isolated *katG* mutant band (MUT1 or MUT2), 123 (96.9%) presented resistance to INH and 11 (8.7%) to Pto. Isolates with *katG* WT loss alone were all high-level INH resistant and Pto susceptible (n=7). Among 62 strains with isolated *inhA* mutant band (MUT1, MUT2, MUT2A, or MUT3B), 51 (82.3%) were INH resistant and 21 (33.9%) were Pto resistant. *inhA* WT loss alone was found in four isolates, of which one (25%) showed high-level INH-resistance and none showed Pto resistance.

Discussion
==========

This study analyzed the relationship between gene mutation pattern and phenotypic INH and Pto resistance using the MTBDR*plus* assay. We analyzed 206 genotypic INH-resistant strains and found that 68.0% had a *katG* mutation and 35.0% had an *inhA* mutation. The presence of *katG* mutation presented high-level INH resistance in most case (94.8%), while over half of the patients with *inhA* mutation (51.5%) showed low-level resistance, which is consistent with previous studies[@B10][@B11][@B12]. However, only 31.8% showed phenotypic Pto resistance in 66 patients with *inhA* mutations.

In our study, *katG* mutations were more frequent in MDR-TB isolates, and *inhA* mutations were significantly more frequent in INH mono-resistant isolates. According to previous studies, the frequency of S315T substitution in the *katG* gene is higher in MDR-TB than in INH mono-resistant TB[@B18][@B19] and might be related to the higher transmission capabilities of MDR-TB[@B20].

Among the isolates with *katG* mutation, MUT1 (S315T) was the most common mutation. This is a transitional mutation G→C (AGC→ACC), resulting in the substitution of serine by threonine (S→T) in the amino acid chain. This S315T mutation has been found in up to 94% of the INH-resistant TB[@B21], which is in agreement with our results. Among the isolates with *inhA* mutation, MUT1 (−15C→T) in the inhA promoter was the most common mutation. This mutation is found in up to 35% of INH-resistant and 55% of Pto-resistant TB[@B22], which is also in agreement with our results.

Phenotypic Pto resistance presented in 8.2% of isolated *katG* mutations and 31.8% of isolated *inhA* mutations. In phenotypic Pto resistant isolates, 61.8% had *inhA* mutation, which agrees with the results of previous studies. Vilcheze and Jacobs[@B22] mentioned that the proportion of *inhA* mutations in Pto-resistant TB is 68% on average, suggesting that this is the main mechanism of Pto resistance in *M. tuberculosis*. Pto is a structural analog of INH used as a second-line drug in the treatment of MDR-TB. Both INH and Pto are classified as pro-drugs that need to be activated by different mycobacterial enzymes. INH is activated by the *katG*-encoded catalaseperoxidase[@B23], and Pto is activated by the NADPH-specific flavin adeninedinucleotide--containing monooxygenase EthA, which is regulated by EthR[@B24]. Once activated, the mode of action of each drug is very similar such that the active forms of the drugs react with NAD+ to yield an INH-NAD or ETH-NAD adduct, which inhibits *inhA*, leading to disruption of mycolic acid biosynthesis and cell death[@B22]. Therefore, mutations at the *inhA* gene can cause cross-resistance to INH and Pto by resulting in the overexpression or modification of the *inhA* target[@B25][@B26]. In addition to the *inhA* mutation, *ndh* mutation causes cross-resistance to both drugs[@B27][@B28], and *ethA*, *ethR*, or *mshA* gene mutation also results in Pto mutation[@B22]. Because *inhA* mutation is considered as the major mechanism of Pto resistance in TB as previously mentioned, the use of LPAs would help physicians to get information about the use of Pto as well as RIF and INH. Nevertheless, few studies have reported the correlation between the results of the MTBDR*plus* assay and phenotypic DST for Pto resistance. Machado et al.[@B25] examined 17 MDR-TB isolates and found that the presence of a mutation in the *inhA* regulatory region together with a mutation in the *inhA* coding region can lead to the development of high-level INH resistance and cross-resistance to Pto. Niehaus et al.[@B29] sought to determine the proportion of patients who could potentially benefit from high-dose INH and who may be resistant to Pto. However, phenotypic Pto resistance was deduced from the *inhA* mutation because phenotypic DST was not performed. Rueda et al.[@B30] examined the relationship between mutations and phenotypic resistance; however, they used whole genome sequencing, which is generally difficult for widespread use in clinical fields. In this study, only 31.8% showed phenotypic Pto resistance in 66 patients with *inhA* mutations, suggesting that Pto may be selected as one of MDR-TB regimen in patients with *inhA* mutation detected by MTBDR*plus* assay until phenotypic DST confirms Pto resistance. There could be two main speculations for the discrepancy between our hypothesis and the results. First, the low reliability and reproducibility of conventional DST of Pto might be the cause of the discrepant results[@B17]. Secondly, other compensatory mechanisms might play a role in maintaining Pto susceptibility in *M. tuberculosis* strains. Tan et al.[@B31] found that mutations in the promoter region of *inhA* and *inhA* gene in Pto-susceptible isolates were different from those in Pto-resistant isolates, and these mutations are more likely to appear together with other mutations in Pto-resistant isolates. They suggested that these mutations may show cumulative effect on increasing minimum inhibitory concentration values of *M. tuberculosis* against Pto. We also speculate that mutations in specific parts of *inhA* may not affect Pto susceptibility.

Although the number of cases in this study was small, isolates with *katG* WT loss alone were all high-level INH resistant, while isolates with *inhA* WT loss alone were INH-resistant in only 25% of cases. Han et al.[@B32] found one of 144 isolates showed low-level INH resistance with *ahpC* mutation confirmed by other LPA (AdvanSure MDR-TB GenoBlot assay), which revealed susceptibility to INH by conventional DST. The authors interpreted that the discrepancy might result from false positive of LPA, low-level resistance suppressing growth of *M. tuberculosis* at 0.2 µg/mL of INH, or hetero-resistance in which susceptible and resistant strains coexist. Therefore, in the case of genotypic INH resistance with isolated *inhA* wild type loss, we recommend that the possibility of an INH susceptible strain should not be ruled out before the final phenotypic DST results are obtained. None of four patients with loss of WT *inhA* band alone showed Pto resistance. Due to the small number of subjects and the absence of gene sequencing data, we could not draw any conclusion from this data. Further studies are needed to reveal the real meaning of this finding.

This study has several limitations. In patients with discrepant results between conventional and molecular DST, gene sequencing, a gold standard method of molecular test, was not performed. The phenotypic DST of second-line drugs such as Pto is considered as an unreliable test, but this test, as a gold standard method, was compared to MTBDR*plus* assay results. Finally, even though we enrolled a large number of isolates with *katG* or *inhA* mutations, the number of isolates with *inhA* WT loss alone was too small to draw any firm conclusion.

The *katG* and *inhA* mutations detected by MTBDR*plus* assay are good indicators of phenotypic INH resistance. However, only about one-third of *inhA* mutations revealed phenotypic Pto resistance, suggesting that Pto may be selected as one of MDR-TB regimen in patients with *inhA* mutation detected by MTBDR*plus* assay until conventional DST confirms phenotypic Pto resistance. We suggest that the reporting of detailed mutation patterns of MTBDR*plus* assay would be important for clinical practice, rather than simply presenting the resistance or susceptibility results.
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###### The baseline characteristics of 206 patients with a genotypic resistance to isoniazid, stratified by the genotypic rifampin resistance

![](trd-82-143-i001)

  Variable                     INH mono-resistance   MDR-TB       Total        p-value
  ---------------------------- --------------------- ------------ ------------ ---------
  No. of subjects              93 (45.1)             113 (54.9)   206 (100)    
  Age, yr                      50.9±16.9             43.0±16.1    46.6±17.0    0.001
  Male sex                     62 (66.7)             70 (61.9)    132 (64.1)   0.482
  BMI, kg/m^2^                 21.3±3.4              21.1±3.0     21.2±3.2     0.745
  Previous TB history          19 (20.4)             60 (53.1)    79 (38.3)    \<0.001
  Concomitant disease                                                          
   Diabetes mellitus           12 (12.9)             19 (16.8)    31 (15.0)    0.435
   Chronic liver disease^\*^   10 (10.8)             3 (2.7)      13 (6.3)     0.017
   Chronic kidney disease      4 (4.3)               1 (0.9)      5 (2.4)      0.177
   Respiratory disease^†^      7 (7.5)               5 (4.4)      12 (5.8)     0.344
   Transplantation             5 (5.4)               2 (1.8)      7 (3.4)      0.248
   Others^‡^                   7 (7.5)               5 (4.4)      12 (5.8)     0.344
  Positive HIV test            1 (1.1)               0 (0)        1 (0.5)      0.451
  Phenotypic DST results                                                       
   INH-mono resistance         75 (80.6)             6 (5.3)      81 (39.3)    
    High-level resistance      54 (58.1)             4 (3.5)      58 (28.2)    
    Low-level resistance       21 (22.6)             2 (1.8)      23 (11.2)    
   MDR-TB                      2 (2.2)               105 (92.9)   107 (51.9)   
   RIF-mono resistance         0 (0)                 2 (1.8)      2 (1.0)      
   Susceptible to INH/RIF      16 (17.2)             0 (0)        16 (7.8)     

Values are presented as number (%).

^\*^Chronic liver disease included alcoholic LC and chronic hepatitis B and C. ^†^Respiratory disease included lung/tracheal cancer (n=4), COPD (n=2), and pneumoconiosis (n=1) in INH-mono resistance, and lung cancer (n=3), COPD (n=1), and IPF (n=1) in MDR-TB. ^‡^Other comorbidities in INH-mono resistant TB patients included Crohn\'s disease (n=2; one with anti-TNF-α therapy and one without), hematologic malignancy without bone marrow transplantation (n=2; one with myelodysplastic syndrome and one with lymphoma), adrenal insufficiency (n=1), c-ANCA associated vasculitis (n=1), and IgA nephropathy with normal kidney function (n=1). MDR-TB patients had rheumatoid arthritis on anti-TNFα therapy (n=1), hematologic malignancy without bone marrow transplantation (n=2; one with acute myeloid leukemia and one with lymphoma), and adrenal insufficiency (n=2).

INH: isoniazid; MDR-TB: multidrug resistant tuberculosis; BMI: body mass index; TB: tuberculosis; HIV: human immunodeficiency virus; DST: drug sensitivity test; RIF: rifampin; LC: liver cirrhosis; COPD: chronic obstructive pulmonary disease; IPF: idiopathic pulmonary fibrosis; TNF-α: tumor necrosis factor α.

###### The mutation patterns of the *katG* and *inhA* genes in 206 patients with a genotypic INH resistance
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  Group                                  INH mono-resistance   MDR-TB       Total        p-value
  -------------------------------------- --------------------- ------------ ------------ ---------
  No. of subjects                        93 (45.1)             113 (54.9)   206 (100)    
  *katG* mutation alone                  55 (59.1)             79 (69.9)    134 (65.0)   0.107
   Mutant probe (+)                      50 (53.8)             77 (68.1)    127 (61.7)   0.035
   Wild-type band loss alone             5 (5.4)               2 (1.8)      7 (3.4)      0.248
  *inhA* mutation alone (%)              37 (39.8)             29 (25.7)    66 (32.0)    0.031
   Mutant probe (+)                      33 (35.5)             29 (25.7)    62 (30.1)    0.126
   Wild-type band loss alone             4 (4.3)               0 (0)        4 (1.9)      0.040
  Both gene mutation                     1 (1.1)               5 (4.4)      6 (2.9)      0.225
   *katG* (MUT1), *inhA* (MUT1)          0 (0)                 2 (1.8)      2 (1.0)      
   *katG* (MUT1), *inhA* (WT1 loss)      1 (1.1)               0 (0)        1 (0.5)      
   *katG* (MUT1), *inhA* (WT2 loss)      0 (0)                 1 (0.9)      1 (0.5)      
   *katG* (WT loss), *inhA* (MUT1)       0 (0)                 1 (0.9)      1 (0.5)      
   *katG* (WT loss), *inhA* (WT2 loss)   0 (0)                 1 (0.9)      1 (0.5)      

Values are presented as number (%).

INH: isoniazid; MDR-TB: multidrug-resistant tuberculosis; *katG* WT: S315 region; *katG* MUT1: S315T\[AGC315ACC\]; *inhA* WT1: positions −15 to −16; *inhA* WT2: positions −8; *inhA* MUT1: C15T.

###### The phenotypic susceptibility to INH and Pto based on the specific mutation patterns of *katG* and *inhA*

![](trd-82-143-i003)

  Mutation                               Total        Phenotypic INH resistance   Phenotypic Pto resistance                
  -------------------------------------- ------------ --------------------------- --------------------------- ------------ -----------
  No. of subjects                        206 (100)    149 (72.3)                  39 (18.9)                   188 (91.3)   34 (16.5)
  *katG* gene alone                      134 (65.0)   127 (94.8)                  3 (2.2)                     130 (97.0)   11 (8.2)
   MUT1 (+)                              119 (57.8)   112 (94.1)                  3 (2.5)                     115 (96.6)   9 (7.6)
   MUT2 (+)                              8 (3.9)      8 (100)                     0 (0)                       8 (100)      2 (25)
   WT (--)/MUT1 (--)/MUT2 (--)           7 (3.4)      7 (100)                     0 (0)                       7 (100)      0 (0)
  *inhA* gene alone                      66 (32.0)    18 (27.3)                   34 (51.5)                   52 (78.8)    21 (31.8)
   MUT1 (+)                              60 (29.1)    17 (28.3)                   34 (56.7)                   51 (85)      21 (35)
   MUT2 (+)                              0 (0)        0 (0)                       0 (0)                       0 (0)        0 (0)
   MUT3A (+)                             1 (0.5)      0 (0)                       0 (0)                       0 (0)        0 (0)
   MUT3B (+)                             1 (0.5)      0 (0)                       0 (0)                       0 (0)        0 (0)
   WT1 (--) and all MUT (--)             4 (1.9)      1 (25)                      0 (0)                       1 (25)       0 (0)
   WT2 (--) and all MUT (--)             0 (0)        0 (0)                       0 (0)                       0 (0)        0 (0)
  Both gene mutation                     6 (2.9)      4 (66.7)                    2 (33.3)                    6 (100)      2 (33.3)
   *katG* (MUT1), *inhA* (MUT1)          2 (1.0)      2 (100)                     0 (0)                       2 (100)      0 (0)
   *katG* (MUT1), *inhA* (WT1 loss)      1 (0.5)      0 (0)                       1 (100)                     1 (100)      0 (0)
   *katG* (MUT1), *inhA* (WT2 loss)      1 (0.5)      0 (0)                       1 (100)                     1 (100)      0 (0)
   *katG* (WT loss), *inhA* (MUT1)       1 (0.5)      1 (100)                     0 (0)                       1 (100)      1 (100)
   *katG* (WT loss), *inhA* (WT2 loss)   1 (0.5)      1 (100)                     0 (0)                       1 (100)      1 (100)

Values are presented as number (%).

INH: isoniazid; Pto: prothionamide; *katG* WT: S315 region; *katG* MUT1, S315T\[AGC315ACC\]; *katG* MUT2, S315T\[AGC315ACA\]); *inhA* WT1: positions −15 to −16; *inhA* WT2: positions −8; *inhA* MUT1: C15T; *inhA* MUT2, A16G; *inhA* MUT3A: T8C; *inhA* MUT3B: T8A.
